DOI: http://dx.doi.org/10.18203/2320-6012.ijrms20221321

Clobetasol propionate 0.025%: a topical therapeutic for skin diseases

Jatinder K. Sadana, Anshuman Rai, Meenu Sethi, Deepshikha Khanna, Suresh K. Jain, Rakesh Bharti, Salman S. Bhoira, Ashish Dhamija, Kiran V. Nabar, Naresh K. Banjara

Abstract


The most widely recommended drugs for the treatment of a variety of dermatoses are topical corticosteroids (TC). These medications are approved for the treatment of inflammatory and pruritic manifestations of dermatologic disorders due to their powerful, symptom-relieving impact. Clobetasol propionate (CP) is the most popular TC used to relieve itching, redness, and edema caused by skin disorders. Topical corticosteroids exhibit anti-inflammatory, anti-pruritic, and vasoconstrictive activities. Clobetasol propionate binds to cytoplasmic glucocorticoid receptors and activates glucocorticoid receptor-mediated gene expression, resulting in the production of anti-inflammatory proteins and suppression of the production of inflammatory mediators. The effectiveness, safety, and clinical experience of utilizing CP 0.025% topical therapy for the treatment of various dermatologic disorders are discussed in this case series.


Keywords


Clobetasol propionate 0.025%, Plaque psoriasis, Psoriasis, Topical corticosteroids

Full Text:

PDF

References


Das A, Panda S. Use of topical corticosteroids in dermatology: An evidence-based approach. Indian J Dermatol. 2017;62(3):237-50.

Sidgiddi S, Naqvi SM, Shenoy M, Balraj DN, Kothari J, Gupta S, et al. Efficacy and safety of novel formulation of clobetasol propionate 0.025% cream in Indian moderate-to-severe psoriasis patients: Phase-2a, randomized 3-arm study. Dermatol Ther (Heidelb). 2021;11(5):1717-32.

Vishwanath V, Chaudhary A, Agarwal A, Jyothi B, Chitharanjan C, Killur LRB, et al. Role of clobetasol propionate 0.025% topical therapy in various dermatoses. Int J Res Med Sci. 2021;9(11):1.

Goldberg B, Hartdegen R, Presbury D, Smith EH, Yawalkar S. A double-blind, multicenter comparison of 0.05% halobetasolpropionate ointment and 0.05% clobetasol propionate ointment in patients with chronic, localized plaque psoriasis. J Am Acad Dermatol. 1991;25(6):1145-8.

Brandon A, Mufti A, Sibbald RG. Diagnosis and management of cutaneous psoriasis: A review. Adv Skin Wound Care. 2019;32(2):58-69.

Draelos ZD, Fowler JF, Cornelison R. A randomized, parallel group, open label, multicenter study to assess the potential for adrenal suppression and systemic drug absorption following multiple dosing with clobetasol propionate cream (Impoyz™), 0.025% versus clobetasol propionate (Temovate®). J Cutan Med Surg. 2018;2(6):410-20.

Jing M, Yu Q, Zhu B, Yuan F, Zhang J, Peng L, et al. Topical 0.05% clobetasol cream in the treatment of chronic hand eczema: A protocol for systematic review and meta-analysis. Medicine. 2021;100(10).